Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53

International Journal of Cancer

Volumn 75, Issue 3, 1998, Pages 391-395

  Zeki, Kazuya ^a   Tanaka, Yoshiya ^a   Morimoto, Isao ^a   Nishimura, Yasuharu ^b   Kimura, Akinori ^c   Yamashita, Uki ^a   Eto, Sumiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; THYROID CARCINOMA;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DNA, NEOPLASM; GENES, P53; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MUTATION; RNA, MESSENGER; THYROID NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032579231     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980130)75:3<391::AID-IJC11>3.0.CO;2-C     Document Type: Article

References (20)

1. BAKER, J.R., The immune response to papillary thyroid cancer. J. clin. Endocrinol. Metab., 80, 3419-3420 (1995).
2. BETTERLE, C., PRESOTTO, F., CARETTO, A., PELIZZO, M.R., PEDINI, B., GIRELLI, M.E. and BUSNARDO, B., Expression of class-I and -II human leukocyte antigens by thyrocytes and lymphocytic infiltration on human thyroid tumors. Cancer, 67, 977-983 (1991).
3. FAGIN, J.A., Tumor-suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J. endocrinol. Invest., 18, 140-142 (1995).
4. FAGIN, J.A., MATSUO, K., KARMAKAR, A., CHEN, D.L., TANG, S.-H. and KOEFFLER, H.P., High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. clin. Invest., 91, 179-184 (1993).
5. FAGIN, J.A., TANG, S.-H., ZEKI, K., DI LAURO, R., FUSCO, A. and GONSKY, R., Re-expression of thyroid peroxidase in a derivative of an undifferentiated thyroid-carcinoma cell line by introduction of wild-type p53. Cancer Res., 56, 765-771 (1996).
6. CIP1/waf1 expression in human breast epithelial cells. Oncogene, 11, 253-261 (1995).
7. HUNT, M.J., HALLIDAY, G.M., WEEDON, D., COOKE, B.E. and BARNETSON, R.S., Regression in basal-cell carcinoma: an immunohistochemical analysis. Brit. J. Dermatol., 130, 1-8 (1994).
8. JUHASZ, F., BOROS, P., SZEGEDI, G., BALAZS, G., SURANYI, P., KRASZITS, E., STENSZKY, V. and FARID, N.R., Immunogenetic and immunologic studies of differentiated thyroid cancer. Cancer, 63, 1318-1326 (1989).
9. + cytotoxic T lymphocytes: requirement of 1a-positive antigen-presenting cells for processing and presentation of tumor antigens. J. Leukocyte Biol., 42, 632-641 (1987).
10. LAHAT, N., SHEINFELD, M., SOBEL, E., KINARTY, A. and KRAIEM, Z., Divergent effects of cytokines on human leukocyte antigen-DR antigen expression of neoplastic and non-neoplastic human thyroid cells. Cancer, 69, 1799-1807 (1992).
11. MARGULIES, L. and SEHGAL, P.B., Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL6) activity by p53 species. J. biol. Chem., 268, 15096-15100 (1993).
12. MATSUBAYASHI, S., KAWAI, K., MATSUMOTO, Y., MUKUTA, T., MORITA, T., HIRAI, K., MATSUZAKA, F., KAKUDOH, K., KUMA, K. and TAMAI, H., The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J. clin. Endocrinol. Metab., 80, 3421-3424 (1995).
13. RAGIMOV, N., KRAUSKOPF, A., NAVOT, N., ROTTER, V., OREN, M. and ALONI, Y., Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene, 8, 1183-1193 (1993).
14. ROPKE, M., REGNER, M. and CLAESSON, M.H., T-cell-rnediated cytotoxicity against p53-protein-derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol., 42, 98-103 (1995).
15. SATO, T., SHLLERI, C., YOUNG, N.S. and MACIEJEWSKI, J.P., Hematopoietic inhibition by interferon-γ is partially mediated through Interferon regulatory factor-1. Blood. 86, 3373-3380 (1995).
16. + T-cell-mediated cytotoxicity. J. Immunol., 152, 1127-1133 (1994).
17. STUBER, G., LEDER, G.H., STORKUS, W.J., LOTZE, M.T., MODROW, S., SZEKELY, L., WOLF, H., KLEIN, E., KARRE, K. and KLEIN, G., Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide-loading-deficient-cell-line assay and a novel major-histocompatibility-complex-class-I-peptide-binding assay. Europ. J. Immunol., 24, 765-768 (1994).
18. TANAKA, N., ISHIHARA, M., LAMPHIER, M.S., NOZAWA, H., MATSUYAMA, T., MAK, T.W., AIZAWA, S., TOKINO, T., OREN, M. and TANIGUCHI, T., Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (Lond.), 382, 816-818 (1996).
19. TANAKA, Y., ADAMS, D.H., HUBSCHER, S., HIRANO, H., SIEBENLIST, U. and SHAW, S., T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature (Lond.), 361, 79-82 (1993).
20. TANAKA, Y., MORIMOTO, I., NAKANO, Y., OKADA, Y., HIROTA, S., NOMURA, S., NAKAMURA, T. and ETO, S., Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. J. Bone Miner. Res., 10, 1462-1469 (1995).